The pro-tumor microenvironment of CLL is already sustained by suppressive soluble factors (e.g., IL-10, TGF-β) and inhibitory immune molecules (e.g., PD-L1, LAG3), among which the tolerogenic milieu [59,60,61,62,63,64] would only be compounded by therapeutics that induce immunosuppressive DAMP release from CLL cells. This evidence concerns the gene IL10 and B-cell chronic lymphocytic leukemia.